NVCHI
REGN icon

New Vernon Capital Holdings II’s Regeneron Pharmaceuticals REGN Stock Holding History

New Vernon Capital Holdings II’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-105
Closed -$75.4K – 74
2023
Q2 		$75.4K Sell
105
-203
-66% -$157K 0.05% 70
2023
Q1 		$253K Hold
308
– – 0.19% 38
2022
Q4 		$222K Hold
308
– – 0.18% 43
2022
Q3 		$212K Sell
308
-248
-45% -$156K 0.22% 21
2022
Q2 		$329K Buy
+556
New +$361K 0.27% 26

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

New Vernon Capital Holdings II's REGN Position: Q3 2023 in Review

New Vernon Capital Holdings II sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 105 shares — an estimated $75.4K sold.

New Vernon Capital Holdings II first reported a position in REGN in Q2 2022 and held it in 5 quarters. The position peaked at $329K in Q2 2022. 1,178 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

  • New Vernon Capital Holdings II reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • New Vernon Capital Holdings II sold 105 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $75.4K.
  • New Vernon Capital Holdings II first reported a position in Regeneron Pharmaceuticals in Q2 2022 and held it in 5 quarters.
  • New Vernon Capital Holdings II's Regeneron Pharmaceuticals position peaked at $329K in Q2 2022.
  • 1,178 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on New Vernon Capital Holdings II's 13F filing for Q3 2023, filed 14 Nov 2023.